Published in Cancer Weekly, August 9th, 2005
Ionix's principal asset is IX-1003, a proprietary intranasal formulation of buprenorphine for acute post-operative pain. Buprenorphine, a well-known opiate analgesic and the intranasal formulation, is being developed to provide rapid pain relief while potentially reducing some side effects associated with opiates. The IX-1003 program, which has completed...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.